{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["evorpacept","venetoclax","azacitidine"]],"indication":"adult acute myeloid leukemia","name":"ASPEN-05","nct_id":"NCT04755244","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aspen-05-nct04755244. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine\n\nPhase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine.","label":"evorpacept (ALX148) + venetoclax + azacitidine","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-08-16","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia","AML, Adult"],"enrollment":{"count":14,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"evorpacept","otherNames":["ALX148"],"type":"DRUG"},{"name":"venetoclax","otherNames":["Venclexta"],"type":"DRUG"},{"name":"azacitidine","otherNames":["Vidaza"],"type":"DRUG"}],"last_update":"2024-11-27","lead_sponsor":"ALX Oncology Inc.","official_title":"A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML) (ASPEN-05)","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-05-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1: Dose Limiting Toxicities (DLT)","timeFrame":"Up to 28 days"},{"measure":"Phase 2: Composite complete remission rate (CRc)","timeFrame":"Approximately 6 months"}],"references":[{"citation":"Marks JA, Wang X, Fenu EM, Bagg A, Lai C. TP53 in AML and MDS: The new (old) kid on the block. Blood Rev. 2023 Jul;60:101055. doi: 10.1016/j.blre.2023.101055. Epub 2023 Feb 14.","pmid":"36841672","type":"DERIVED"}],"start_date":{"date":"2021-05-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)","url":"https://clinicaltrials.gov/study/NCT04755244"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aspen-05-nct04755244"}